LONDON, September 25 /PRNewswire/ --

Morria Biopharmaceuticals Plc, a private biopharmaceutical company
focusing on first-in-class, novel non-steroidal anti-inflammatory drugs,
today announced it has appointed Dr. Johnson Lau and Dr. David Sidransky to
its board of directors.

Dr. Johnson Lau (MBBS, MD, FRCP) brings a wealth of experience from the
medical, pharmaceutical and corporate fields, having a distinguished
background in both academic medicine and executive-level management of
pharmaceutical and biotechnology companies. Dr. Lau previously served
Schering-Plough, ICN Pharmaceuticals and its subsidiary Ribapharm, and is
currently a senior advisor to Novartis. He was formerly a managing director
of healthcare investment banking of Roth Capital Partners. Dr. Lau also
serves as a member of the board of directors of Chelsea Therapeutics,
VioQuest Pharmaceuticals, XenoBiotic Laboratories and Kinex Pharmaceuticals.
Dr. Lau is a Fellow of the Royal College of Physicians of the United Kingdom.
He received both his medical degree and doctoral degree from the University
of Hong Kong.

Dr. David Sidransky (MD) is the director of the Head and Neck Cancer
Research Division at Johns Hopkins University School of Medicine and is also
a professor of oncology, otolaryngology-head and neck surgery, cellular and
molecular medicine, urology, and genetics and pathology at the university. He
is currently vice-chairman of the board of directors of ImClone Systems, lead
independent chairman at Alfacell Inc. and serves on the board of directors of
Zila Inc. and Xenomics. Dr. Sidransky is a founder of several private
biotechnology companies and has served on numerous scientific advisory boards
of both private and public companies, including Medimmune, Telik, Roche and
Amgen. He was formerly on the board of scientific counselors at the National
Institute of Dental and Craniofacial Research and is a member of the
Recombinant DNA advisory committee at the National Institutes of Health. Dr.
Sidransky sits on numerous editorial boards and has served as senior editor
of several cancer-related journals. He is certified in internal medicine and
medical oncology by the American Board of Medicine.

"We are excited to have Dr. Lau and Dr. Sidransky join Morria's board,"
said Mark Cohen, chairman of the board. "Their extensive pharmaceutical and
corporate experience will provide valuable guidance in both our clinical
development plan with our lead anti-inflammatory compounds and the
development of the company from a corporate perspective."

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on
the development of novel anti-inflammatory pharmaceuticals known as
multi-functional anti-inflammatory drugs (MFAIDs). The company's objective is
to become a pivotal player in the anti-inflammatory drug market through the
introduction of novel drugs for the treatment of a variety of acute and
chronic inflammatory conditions including skin, pulmonary and
gastro-intestinal inflammatory diseases. For more information please visit
www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for
shares. This release is only intended for persons falling within the
exception set out in regulation 47 of the Financial Promotion order - persons
in the business of disseminating information.

SOURCE: Morria Biopharmaceuticals Plc 
    
    UK CONTACT: Yuval Cohen, President
    53 Davies Street, London, W1K 5JH, United Kingdom
    Tel: +44-(0)-207-152-6341 or info@morria.com

    US CONTACT: Greg Tiberend
    Richard Lewis Communications, Inc.
    35 West 35 St., Suite 505, New York, NY 10001
    Tel: +1-212-827-0020 or gtiberend@rlcinc.com



Web site: http://www.morria.com